Providers endorse medical marijuana for kids with cancerDecember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatrics
A+AVD improves modified PFS in advanced HLDecember 14, 2017Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Technique may be effective for diagnosing NHLDecember 14, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Combo prolongs survival in lymphoma modelsDecember 1, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Inhibitor exhibits activity against range of lymphomasNovember 30, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Mogamulizumab BLA receives priority reviewNovember 29, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
How CLL patients weigh treatment efficacy, safety, and costNovember 26, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Review suggests low incidence of BIA-ALCL in CanadaNovember 25, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
CCSs have increased risk of hypertensionNovember 24, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Method identifies effective treatments for leukemias, lymphomasNovember 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLALLNon-Hodgkin LymphomaAggressive Lymphomas
PTSD can persist in cancer survivorsNovember 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated Issues
FDA expands approval of obinutuzumabNovember 17, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Parity laws don’t lower oral cancer drug costs for everyoneNovember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated Issues
CHMP wants to expand use of BV to include CTCLNovember 14, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA approves brentuximab vedotin for pcALCL, MFNovember 10, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma